15 May Cambridge Major to build new pharma plant
Germantown, Wis. – Cambridge Major Laboratories says it will build a new 120,000-square-foot plant next to its Germantown headquarters, enabling the company to expand into large-scale active pharmaceutical ingredient manufacturing.
The facility, which will contain multiple manufacturing suites that are capable of making multi-ton quantities of active pharmaceutical ingredients (APIs), is scheduled for completion in August of 2009.
Since opening a small-volume manufacturing site in 2004, Cambridge Major has built a growing pipeline of APIs, but it now needs more capacity for later-stage clinical and commercial production. It already has three API development sites in the United States and Europe, and they will feed large-scale manufacturing at the new site.
Michael Major said it’s “vitally important” for the company to extend its service offerings because it has a number of projects in Phase III clinical trials. The company, established in 1999, wants to continue on the 30 percent annual growth rate it has experienced since its inception.
• Cambridge Major acquires Netherlands pharma company
• Cambridge Major appoints Hartwig as scientific advisor
• Germantown drug company hires pharma veteran James Davidson as COO